Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Tirbanibulin 1% ointment demonstrated significant effectiveness in the treatment of actinic keratosis (AK), with an odds ratio (OR) of 11.1 (95% CI (confidence interval): 6.2-20.9) for complete clearance of lesions, comparable to treatments like ingenol mebutate (OR 12.5) and photodynamic therapy (OR 11.7). However, it is less effective than fluorouracil 4% and 5% (OR 30.3 and 35.0, respectively).
• The effectiveness of tirbanibulin is better than that of diclofenac 3% (OR 2.9), highlighting its value as a treatment option for AK. These findings apply to general populations with AK, with no specific subgroup analyses mentioned.
• The safety profile of tirbanibulin 1% for actinic keratosis (AK) was assessed qualitatively and found to be favorable, with no specific adverse effects or safety concerns reported in the available evidence.
• Long-term efficacy and safety data for tirbanibulin 1% are not currently available, according to the systematic review.
• There is no population type or subgroup information available in the reviewed studies.